Evidence map›Paper›PMID 29607371›Full record

ArticleVirusdisease2018

Efficacy of H120 and Ma5 avian infectious bronchitis vaccines in early challenge against QX strain.

Vahid Karimi, Arash Ghalyanchilangeroudi, Masoud Hashemzadeh, Forough Rahimi, Mohammad Taha Zabihi Petroudi, Reza Kh Farahani, Hossein Maghsoudloo, Hamed Abdollahi

Erratum issuedAbstract read
In one paragraph

Article in Virusdisease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Vahid Karimi1Department of Poultry Diseases, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Arash Ghalyanchilangeroudi2Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Masoud Hashemzadeh3Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Tehran, Iran.
Forough Rahimi1Department of Poultry Diseases, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Mohammad Taha Zabihi Petroudi1Department of Poultry Diseases, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Reza Kh FarahaniIranian Veterinary Organization, Tehran, Iran.
Hossein MaghsoudlooIranian Veterinary Organization, Tehran, Iran.
Hamed AbdollahiIranian Veterinary Organization, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infectious bronchitis (IB) is a highly infectious avian pathogen, which affects the respiratory tract, gut, reproductive system, and kidney of chicks of all ages. Many different serotypes of IB virus (IBV) are recognized which cause different clinical manifestations. According to the antigenic differences, different serotypes of the virus do not cross-protect. Massachusetts serotype induces the best cross-protection against other serotypes. Recently, the IBV QX strain has been detected in Iran. QX strain causes permanent damage to the oviduct if it occurs in the early life cycle and is a significant factor in layer and breeder chicken flocks. In this study, we compare the H120 and Ma5 vaccines' protection against early challenge with the QX strain in commercial chicks. one-day-old commercial chicks were divided into six groups. Groups 1 and 2 were unvaccinated groups. Groups 3 and 5 were vaccinated with the H120 vaccine (eye drop) and groups 4 and 6 were vaccinated with Ma5 (eye drop) on the 6th day (5 days after vaccination). Groups 2, 3 and 4 challenged (oculonasal) with QX strain (10^

Indexed as

Cross-protectionEarly challengeInfectious bronchitis virus (IBV)Vaccination

Identifiers

PMID29607371
PMCPMC5877842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.